Neurocrine Biosciences, Inc.
12790 El Camino Real
San Diego
California
92121
United States
Tel: 858-617-7600
Fax: 858-617-7601
Website: http://www.neurocrine.com/
405 articles with Neurocrine Biosciences, Inc.
-
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2019 Financial Results
10/14/2019
Conference Call and Webcast Scheduled for Monday, November 4
-
Neurocrine Biosciences Presents New Data Analyses Demonstrating Long-Term Effects of INGREZZA® (valbenazine) 40 mg Once-Daily in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress
10/4/2019
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced data from pooled analyses demonstrating the long-term benefit of the once-daily 40 mg dose of INGREZZA® (valbenazine) capsules in reducing abnormal movements in adults with tardive dyskinesia (TD), a potentially irreversible and often persistent involuntary movement disorder.
-
Neurocrine Biosciences to Present Data Analyses Demonstrating the Long-Term Effectiveness of INGREZZA® (valbenazine) in Patients with Tardive Dyskinesia at the 2019 Annual Psych Congress
10/1/2019
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced it will present data analyses evaluating the long-term effects of once-daily 40 mg INGREZZA® (valbenazine) in adults with tardive dyskinesia (TD), an involuntary movement disorder.
-
Neurocrine Biosciences Appoints David W. Boyer as Chief Corporate Affairs Officer
9/30/2019
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that David W. Boyer has joined the company's executive management team as Chief Corporate Affairs Officer
-
Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) for Tardive Dyskinesia; Opicapone and VY-AADC for Parkinson's Disease, at the 2019 International Congress of Parkinson's Disease and Movement Disorders®
9/17/2019
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced it will present data analyses from its movement disorder programs, including INGREZZA® (valbenazine) capsules, the first U.S. Food and Drug Administration (FDA) approved treatment for adults with tardive dyskinesia (TD); opicapone, an investigational adjunctive treatment for Parkinson's disease (PD) in the U.S.; and VY-AADC, a gene therapy for PD acquired through a strategic collaboration with Voyager Therapeutics.
-
Neurocrine Biosciences Announces Appointment of Leslie V. Norwalk to Board of Directors
9/11/2019
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced the appointment of Leslie V. Norwalk to its Board of Directors.
-
There are high hopes for more M&A in the industry for the remainder of the year. Here’s a look at the 10 top takeover targets.
-
Neurocrine Biosciences to Present at Upcoming Healthcare Conferences - Aug. 28, 2019
8/28/2019
Neurocrine Biosciences, Inc. announced that Neurocrine Biosciences management will present at the following investor conferences
-
AbbVie Submits New Drug Application to US FDA for Investigational Elagolix for Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Women
8/5/2019
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, in cooperation with Neurocrine Biosciences, Inc. (NASDAQ: NBIX), today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for elagolix
-
Neurocrine Biosciences Reports Second Quarter 2019 Financial Results
7/29/2019
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter ended June 30, 2019 and provided an update on the launch of INGREZZA® (valbenazine) and its clinical development programs.
-
Neurocrine Biosciences Announces FDA Acceptance of New Drug Application for Opicapone as an Adjunctive Treatment for Patients with Parkinson's Disease
7/10/2019
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for opicapone, a novel, once-daily, oral, selective catechol-O-methyltransferase (COMT) inhibitor as an adjunctive treatment to levodopa/carbidopa in patients with Parkinson's disease experiencing OFF episodes.
-
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2019 Financial Results
7/8/2019
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it will report second quarter financial results after the Nasdaq market closes on Monday, July 29, 2019
-
“Our alliance with Sanofi Genzyme has been foundational for Voyager as we optimized the development of capsids, transgenes and gene therapy delivery,” stated Andre Turenne, president and chief executive officer of Voyager. “We look forward to this new stage of the relationship and to advancing ou...
-
Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) and Opicapone at the 2019 World Congress on Parkinson's Disease and Related Disorders
6/11/2019
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced it will present data from two of its movement disorder programs, including INGREZZA® (valbenazine) capsules, the first U.S. Food and Drug Administration (FDA) approved treatment for adults with tardive dyskinesia (TD), and opicapone, an investigational adjunct treatment for Parkinson's disease.
-
Neurocrine Biosciences to Present at Goldman Sachs 40th Annual Global Healthcare Conference
6/4/2019
Neurocrine Biosciences, Inc. will present at the Goldman Sachs 40th Annual Global Healthcare Conference at 10:00 a.m. PT (1:00 p.m. ET) on Tuesday, June 11, 2019, in Rancho Palos Verdes, Calif. Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, of Neurocrine Biosciences will present at the conference.
-
Neurocrine Biosciences to Present at Jefferies 2019 Global Healthcare Conference
5/30/2019
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) will present at the Jefferies 2019 Global Healthcare Conference at 10:30 a.m. ET on Thursday, June 6, 2019, in New York. Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, of Neurocrine Biosciences will present at the conference.
-
Biocom Appoints Additional Members to Board of Directors
5/29/2019
Biocom, the association representing the California life science industry, today announced that it has added Matt Abernethy, chief financial officer of Neurocrine Biosciences, and Sabrina Martucci Johnson, president and chief executive officer of Daré Biosciences, to its board of directors.
-
Neurocrine Biosciences Presents New Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia, Demonstrating the Effect of Involuntary Movements on Patient Quality of Life
5/20/2019
Neurocrine Biosciences, Inc. announced new data from RE-KINECT, the largest real-world screening study to date of patients with clinician-confirmed possible tardive dyskinesia, demonstrating the effect of involuntary movements on patient health-related quality of life.
-
Neurocrine Biosciences to Present New Quality-of-Life Data Analysis from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia Patients, at the 2019 American Psychiatric Association Annual Meeting
5/16/2019
Neurocrine Biosciences, Inc. announced that it will present a new quality-of-life data analysis from RE-KINECT, the largest real-world screening study of patients with clinician-confirmed possible tardive dyskinesia, an involuntary movement disorder.
-
Almost every week, biopharma companies release results from ongoing clinical trials. Here’s a roundup of some of the top clinical trial news from the previous week.